Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 YearsSan Diego, CA, June 25, 2025 (GLOBE NEWSWIRE) -- Gordon Schanzlin New Vision Institute ...

Every June is Cataract Awareness Month. It is a communication month designated by seniors over 50 and their families, medical ...

In the U.S. market, we currently have three newer multifocal IOLs approved for use: the Alcon Clareon PanOptix Pro, the ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the ...

Purpose To establish and validate a universal artificial intelligence (AI) platform for collaborative management of cataracts involving multilevel clinical scenarios and explored an AI-based medical ...

Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist. Read why ALC stock is a hold.

Alcon is the sixth-largest medical device maker in Orange County and is considered to be the largest eye care company in the world, valued at $35.1 billion (NYSE: ALC). It employs more than 25,000, ...

Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptyr; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED) 1,2 brings to ...

Cataracts form because of something has changed metabolically in the lens that has caused a true opacification. And it's always, it's always kind of an odd thing to say, ‘Well, nuclear sclerosis is a ...

LOS ANGELES — With the recently launched Unity system, Alcon aims to allow ophthalmologists to perform vitreoretinal cataract surgery and cataract surgery on the same platform. According to a ...

Prevent Blindess has declared June as Cataract Month to provide patients, care partners, and health professionals with free educational resources on cataract. 1 The organization is providing resources ...

Alcon expects to launch the product in the third quarter of 2025. This article originally appeared on MPR. References: Alcon announces FDA approval of Tryptyr (acoltremon ophthalmic solution) 0.003% ...